Mizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat October 20, 2015 10:22 AM CIBC Downgrades Valeant Pharmaceuticals (VRX) to Sector PerformOctober 20, 2015 7:26 AM BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance October 20, 2015 6:42 AM Market Wrap: China Data Stunts Markets; Weight Watchers Inks Major Deal; Western Digital/SanDisk Deal NearsOctober 19, 2015 5:24 PM Valeant seriously considering the sale of neuro assetsOctober 19, 2015 9:21 AM Valeant CEO sees new drug pricing environment aheadOctober 19, 2015 6:13 AM Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS OutlookOctober 19, 2015 6:10 AM Valeant Pharmaceuticals Reports Third Quarter 2015 Financial ResultsOctober 19, 2015 6:00 AM Top 10 News for 10/9 - 10/16: Dell's Big Buy; Wal-mart's Dire Outlook; Twitter's Busy Week; Square's Imminent IPOOctober 16, 2015 3:58 PM Trading Radar for 10/19: Morgan Stanley (MS), IBM (IBM), Halliburton (HAL), Genuine Parts (GPC), Rambus (RMBS) ReportOctober 16, 2015 3:11 PM